Myeloproliferative neoplasm secondary prevention

Jump to navigation Jump to search

Myeloproliferative Neoplasm Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating myeloproliferative neoplasm from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myeloproliferative neoplasm secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myeloproliferative neoplasm secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myeloproliferative neoplasm secondary prevention

on Myeloproliferative neoplasm secondary prevention

Myeloproliferative neoplasm secondary prevention in the news

Blogs on Myeloproliferative neoplasm secondary prevention

Directions to Hospitals Treating Myeloproliferative neoplasm

Risk calculators and risk factors for Myeloproliferative neoplasm secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Secondary prevention measures include routine monitoring of laboratory values, including complete blood count (CBC) and metabolic panel.

Secondary Prevention

Secondary prevention measures include routine monitoring of laboratory values, including complete blood count (CBC) and metabolic panel. The frequency of laboratory checks varies depending on the severity disease and the clinical assessment.[1]

References

  1. National Cancer Institute. Physician Data Query Database 2015.http://www.cancer.gov/types/myeloproliferative

Template:WH Template:WS